These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10552124)

  • 1. Use of possible synergistic expression of p53 and p185 as a prognostic tool for stage I non-small-cell lung cancer.
    Cantero R; Torres AJ; Maestro M; Fernández C; Hernando F; del Barco V; Sanz T; Balibrea JL
    World J Surg; 1999 Dec; 23(12):1294-9; discussion 1299-300. PubMed ID: 10552124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue.
    Diez M; Pollán M; Maestro M; Torres A; Ortega D; Gómez A; Sánchez A; Hernando F; Balibrea JL
    Br J Cancer; 1997; 75(5):684-9. PubMed ID: 9043025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the quantified expression of p185 in non-small cell lung cancer.
    Cantero R; Torres AJ; Maestro ML; Hernando F; Sanz MT; Del Barco V; Gómez A; Fernández C; Balibrea JL
    J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1119-25. PubMed ID: 10838527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
    Lee JS; Yoon A; Kalapurakal SK; Ro JY; Lee JJ; Tu N; Hittelman WN; Hong WK
    J Clin Oncol; 1995 Aug; 13(8):1893-903. PubMed ID: 7636531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer.
    Shi D; He G; Cao S; Pan W; Zhang HZ; Yu D; Hung MC
    Mol Carcinog; 1992; 5(3):213-8. PubMed ID: 1350198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
    Mitsudomi T; Suzuki S; Yatabe Y; Nishio M; Kuwabara M; Gotoh K; Hatooka S; Shinoda M; Suyama M; Ogawa M; Takahashi T; Ariyoshi Y; Takahashi T
    J Natl Cancer Inst; 1998 Oct; 90(20):1563-8. PubMed ID: 9790550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
    Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
    Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
    Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
    Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.
    Lai RS; Wang JS; Hsu HK; Chang HC; Lin CH; Lin MH
    Jpn J Clin Oncol; 2002 Oct; 32(10):393-7. PubMed ID: 12451034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.